English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT03918278 /

MK-0482-001

A Phase 1b, Open-Label, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of MK-0482 As Monotherapy And In Combination With Pembrolizumab In Participants With Advanced/Metastatic Solid Tumors.

DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: